Patents by Inventor Nupam Mahajan

Nupam Mahajan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NXTAR-derived oligonucleotides and uses thereof
    Patent number: 12194057
    Abstract: Among the various aspects of the present disclosure is the provision of a NXTAR-derived oligonucleotides and uses thereof. An aspect of the present disclosure provides for a method of (i) suppressing androgen receptor (AR) expression, (ii) suppressing androgen receptor splice variants (including AR-V7) expression, (iii) treating cancer (e.g., prostate, breast, testis, ovarian, endometrial and skin) (iv) treating skin related diseases, such as androgenetic alopecia and acne vulgaris in a subject comprising administering to the subject a NXTAR-derived oligonucleotide (oligo) (NXTAR is a lncRNA also known as LOC105373241).
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: January 14, 2025
    Assignee: Washington University
    Inventor: Nupam Mahajan
  • ALLOSTERIC INHIBITOR OF WEE1 KINASE
    Publication number: 20240308971
    Abstract: Disclosed are WEE1 inhibitors and their use in methods of inhibiting a WEE1 epigenetic activity or treating cancer having WEE1 epigenetic activity.
    Type: Application
    Filed: May 20, 2024
    Publication date: September 19, 2024
    Inventors: Nupam MAHAJAN, Nicholas LAWRENCE
  • Allosteric inhibitor of WEE1 kinase
    Patent number: 11987568
    Abstract: Disclosed is a method for selecting a cancer therapeutic for a patient that involves assaying a tumor biopsy sample from the subject to detect PAXIP1 expression, and selecting a WEE1 inhibitor as the cancer therapeutic if PAXIP1 is detected in the tumor biopsy sample.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: May 21, 2024
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventors: Nupam Mahajan, Nicholas Lawrence
  • NXTAR-DERIVED OLIGONUCLEOTIDES AND USES THEREOF
    Publication number: 20220193110
    Abstract: Among the various aspects of the present disclosure is the provision of a NXTAR-derived oligonucleotides and uses thereof. An aspect of the present disclosure provides for a method of (i) suppressing androgen receptor (AR) expression, (ii) suppressing androgen receptor splice variants (including AR-V7) expression, (iii) treating cancer (e.g., prostate, breast, testis, ovarian, endometrial and skin) (iv) treating skin related diseases, such as androgenetic alopecia and acne vulgaris in a subject comprising administering to the subject a NXTAR-derived oligonucleotide (oligo) (NXTAR is a lncRNA also known as LOC105373241).
    Type: Application
    Filed: December 17, 2021
    Publication date: June 23, 2022
    Applicant: Washington University
    Inventor: Nupam Mahajan
  • ALLOSTERIC INHIBITOR OF WEE1 KINASE
    Publication number: 20210309630
    Abstract: Disclosed is a method for selecting a cancer therapeutic for a patient that involves assaying a tumor biopsy sample from the subject to detect PAXIP1 expression, and selecting a WEE1 inhibitor as the cancer therapeutic if PAXIP1 is detected in the tumor biopsy sample.
    Type: Application
    Filed: August 2, 2019
    Publication date: October 7, 2021
    Inventors: Nupam MAHAJAN, Nicholas LAWRENCE
  • Methods for diagnosis and prognosis of epithelial tumors
    Patent number: 10655185
    Abstract: A biomarker is disclosed that can distinguish aggressive epithelial tumors in a tissue biopsy from, for example, normal, hyperplastic, and benign neoplastic tumors. The biomarker can also identify epithelial tumors that have become resistant to hormone therapy. Therefore, methods are disclosed for providing diagnosis and prognosis of a subject having, or suspected of having, an epithelial tumor, such as a prostate tumor.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 19, 2020
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of Center Florida Research Foundation, Inc.
    Inventors: Ratna Chakrabarti, Richard Ottman, Domenico Coppola, Nupam Mahajan
  • METHODS FOR DIAGNOSIS AND PROGNOSIS OF EPITHELIAL TUMORS
    Publication number: 20170335403
    Abstract: A biomarker is disclosed that can distinguish aggressive epithelial tumors in a tissue biopsy from, for example, normal, hyperplastic, and benign neoplastic tumors. The biomarker can also identify epithelial tumors that have become resistant to hormone therapy. Therefore, methods are disclosed for providing diagnosis and prognosis of a subject having, or suspected of having, an epithelial tumor, such as a prostate tumor.
    Type: Application
    Filed: November 10, 2015
    Publication date: November 23, 2017
    Inventors: Ratna Chakrabarti, Richard Ottman, Domenico Coppola, Nupam Mahajan